CareDx Completes Acquisition of Naveris to Add Specialty Oncology Diagnostics Platform
CDNA•CareDx completed the acquisition of Naveris, adding a specialty oncology diagnostics business to its offering and extending its leadership in high-growth oncology testing. Integration of Naveris's diagnostic assays into CareDx's laboratory network is expected to diversify revenue beyond transplant markets.
1. Acquisition Expands Oncology Portfolio
On July 1, 2026, CareDx finalized the purchase of Naveris, a specialty oncology diagnostics developer, marking its entry into the high-growth oncology testing sector. Naveris's diagnostic assays will be integrated into CareDx’s existing laboratory infrastructure, positioning the combined company to leverage rising demand for advanced oncology diagnostics and diversify beyond transplant testing.
